Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 8/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | CCKAR | P32238 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3901443 | 0.93 | KMT2A (0.37) | KDM1ACCKBRCCR1ACLYKDM4E | |
| SCHEMBL3901386 | 0.92 | CCKBR (0.40) | CCKBRACLYKDM4ETACR1MCL1 | |
| SCHEMBL3902511 | 0.92 | CCKBR (0.46) | CCKBRCCR2CCKAR | |
| SCHEMBL3901201 | 0.89 | CCKBR (0.41) | CCKBRCCR2CCKAR | |
| SCHEMBL3900438 | 0.89 | CCKBR (0.44) | CCKBRCCR2CCKAR | |
| SCHEMBL3897448 | 0.89 | CCKBR (0.41) | CCKBRCCKARFLT1FLT4KDR | |
| SCHEMBL3902490 | 0.87 | CCKBR (0.53) | CCKBRKDM4ECCKAR | |
| SCHEMBL3753898 | 0.84 | KDM1A (0.39) | KDM1ACCKBRACLYUSP36CCKAR | |
| SCHEMBL3896521 | 0.82 | KMT2A (0.38) | CCKBRCCKAR | |
| SCHEMBL3900281 | 0.82 | KMT2A (0.38) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | claimed |
| US-7550492-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-23 | — | — | US | disclosed |
| US-20070276016-A1 | BENZO[1,2,5]THIADIAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | US | disclosed |
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| EP-1675837-A2 | BENZO [1,2,5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005012275-A2 | BENZO [1, 2, 5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| US-20040224983-A1 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276016-A1 | BENZO[1,2,5]THIADIAZOLE COMPOUNDS | CCKBR, CCKAR, GIPR | KDM1A 3752/4885CCKBR 1/4885CCR1 1685/4885 |
| US-20040224983-A1 | Benzo[1,2,5]thiadiazole compounds | CCKBR, CCKAR, BRSK2 | KDM1A 3148/4885CCKBR 1/4885CCR1 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.